Industry news that matters to you.  Learn more

Foundation Medicine Announces Collaboration with Array BioPharma

Reading time: 2 minutes

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, recently announced a collaboration with Array BioPharma (NASDAQ: ARRY). Foundation Medicine will use its genomic sequencing and analytic capabilities to assess potentially relevant molecular alterations to assist Array in targeting patients that are most likely to respond to treatment.

“Foundation Medicine has established a remarkable portfolio of collaborations around the discovery and clinical development of targeted cancer therapeutics,” said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. “The molecular information generated by our platform is designed to help biopharma companies like Array expedite the development of targeted drug candidates that impact the genomic pathways driving a specific cancer.”

Array has a portfolio of targeted cancer agents in early stages of clinical development. Through this collaboration with Foundation Medicine, Array intends to determine the genetic profile of tumors of patients who are treated with certain of its anticancer agents. The goal of this work is to understand how to identify patients who may respond to a given targeted therapy to ensure that each patient gets the optimal drug to treat their individual disease.

Foundation Medicine’s industry and academic partnerships complement the company’s core cancer diagnostics capability, a comprehensive cancer genomic test that provides physicians with genomic information that may help match patients with treatments or clinical trials specific for the genomic profile of their tumor.

Source: Foundation Medicine